@article{TLCR28754,
author = {Paul Hofman},
title = {First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {5},
year = {2019},
keywords = {},
abstract = {A certain number of patients with advanced stage or metastatic non-small cell lung cancer (NSCLC) show better overall survival when treated with first-line immunotherapy than patients treated with chemotherapy (1). This finding, originally reported in KEYNOTE-024, has just been updated and continues to confirm, for the same cohort of patients, benefit from first-line pembrolizumab treatment (1,2).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/28754}
}